/
CAMP
$4.44+$0.24 (+5.71%)live
Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Market cap
$218.1M
52M shares
52-week range
$1.32 – $7.75
49% from low
Sector
PHARMACEUTICAL PREPARATIONS
Exchange
NASDAQ
CS
Borrow rate
2.46%
Moderate
Price (6 mo)
Loading chart…
Change$-290.42
Valuation
Financials
Loading chart…
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $363.8M | $366.1M | $308.6M | $295.8M | $0 | $350.0K | $652.0K | $3.5M |
| Cost of revenue | $216.0M | $222.8M | $186.2M | $174.0M | $0 | $0 | $0 | $1.6M |
| Gross profit | $147.8M | $143.3M | $122.4M | $121.9M | −$947.0K | $350.0K | $652.0K | $1.9M |
| Gross margin | 40.6% | 39.1% | 39.7% | 41.2% | — | 100.0% | 100.0% | 53.1% |
| R&D | $27.7M | $29.4M | $25.8M | $28.4M | $34.8M | $40.6M | $38.8M | $38.2M |
| Operating income | $19.7M | −$16.8M | −$3.9M | −$15.3M | −$45.0M | −$51.9M | −$53.1M | −$52.1M |
| EBITDA | $47.1M | $15.2M | $18.1M | $7.5M | −$44.1M | −$50.2M | −$51.4M | −$50.4M |
| Net income | $18.4M | −$78.8M | −$21.2M | −$31.1M | −$44.2M | −$49.3M | −$51.8M | −$80.4M |
| Net margin | 5.1% | -21.5% | -6.9% | -10.5% | — | -14083.1% | -7943.4% | -2298.5% |
| EPS (diluted) | 0.52 | -2.34 | -0.62 | -0.88 | -0.90 | -4.07 | -2.66 | -2.65 |
Annual figures · source: Financial Modeling Prep
Analyst estimates (consensus)
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $6M | $-0.81 | $-1.01–$-0.66 | 5 |
| 2027 | $6M | $-0.73 | $-0.88–$-0.56 | 5 |
| 2028 | $2M | $-0.78 | $-0.97–$-0.49 | 6 |
| 2029 | $12M | $-0.74 | $-1.20–$-0.08 | 4 |
Forward consensus · source: Financial Modeling Prep
DCF fair valuemodel estimate
Intrinsic value
$2.88
Price
$4.44
Implied downside
-35%
Peer comparison
CAMP4 Therapeutics Corporation Common Stock
Camp4 Therapeutics Corp is a clinical-stage biopharmaceutical company pioneering the discovery and development of regulatory RNA-based therapeutics to upregulate gene expression and restore healthy protein levels to treat various genetic diseases. The company focuses on genetic diseases of the central nervous system and liver. Its pipeline products include CMP-CPS-001 and CMP-SYNGAP. The company operates as a single operating segment, R&D, which engages in the development of a new class of RNA-based therapeutics to treat a broad range of genetic diseases.
www.camp4tx.com- Employees
- 48
- IPO / List date
- Oct 11, 2024
- HQ
- CAMBRIDGE, MA
Held by traders on TradeandTell
No one on the platform currently holds CAMP.
Super investors & insiders
Institutions holding (13F)
No tracked institution reports a position in CAMP as of their last filing.
Insider activity (SEC Form 4)
Stock splits
| Execution date | Ratio |
|---|---|
| 2024-02-02 | 1-for-23reverse |
Recent trades on TradeandTell
No one on the platform has traded CAMP yet.
